The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Value Expansion Is Expected For The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Over The Forecast Period?
The warm autoimmune hemolytic anemia (waiha) treatment market size has seen substantial growth over recent years. Its value is projected to increase from $0.6 billion in 2025 to $0.65 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.2%. The historical expansion of this market can be attributed to elements such as reliance on corticosteroid therapy, limited treatment options, hospital-based autoimmune care, blood transfusion dependency, and low disease awareness.
The market for warm autoimmune hemolytic anemia (WAIHA) treatments is projected to experience substantial expansion over the upcoming years. By 2030, this market is anticipated to reach $0.93 billion, exhibiting a compound annual growth rate (CAGR) of 9.2%. Factors contributing to this projected growth include advancements in biologic drugs, enhanced autoimmune diagnostic capabilities, the spread of precision medicine, an expanding elderly demographic, and the development of specialized hematology care. Key developments expected during the forecast period encompass a greater reliance on monoclonal antibody therapies, an uptick in steroid-sparing treatment options, the widening scope of personalized autoimmune therapies, an increasing significance of IVIG in acute care, and more refined diagnostic and monitoring procedures.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24426&type=smp
What Are The Main Drivers Accelerating The Growth Of The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market?
The warm autoimmune hemolytic anemia (WAIHA) treatment market is anticipated to experience growth, primarily fueled by increasing healthcare expenditure. This expenditure encompasses the total resources dedicated to health services, covering prevention, diagnosis, treatment, and disease management, by individuals, governments, and various organizations. Advances in medical technology contribute to the rise in healthcare spending, as newer diagnostic tools and treatments often involve higher costs for their development, implementation, and ongoing patient care. Healthcare expenditure supports warm autoimmune hemolytic anemia (WAIHA) treatment by allocating funds for research, facilitating access to advanced diagnostic tools, and ensuring the availability of specialized therapies crucial for managing and controlling the disease. For instance, in May 2024, data from the Office for National Statistics, a UK-based government agency, indicated that long-term health and social care expenditures in real terms increased by 2.8% in 2022, while overall healthcare spending rose by 5.6% in 2023. Consequently, the expanding healthcare expenditure is a key driver for the growth of the warm autoimmune hemolytic anemia (WAIHA) treatment market.
How Is The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Distributed Across Key Segments?
The warm autoimmune hemolytic anemia (waiha) treatment market covered in this report is segmented –
1) By Treatment Type: Corticosteroids, Monoclonal Antibodies, Intravenous Immunoglobulin (IVIG), Blood Transfusions, Splenectomy
2) By Route Of Administration: Oral, Intravenous, Subcutaneous
3) By Patient Demographics: Children, Adults, Geriatric
4) By Therapeutic Area: Primary Autoimmune Disorders, Secondary Autoimmune Disorders, Genetic Predisposition
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Corticosteroids: Prednisone, Dexamethasone, Methylprednisolone
2) By Monoclonal Antibodies: Rituximab, Sutimlimab, Bortezomib
3) By Intravenous Immunoglobulin: Standard IVIG, High-Dose IVIG Therapy, Pooled Plasma-Derived Immunoglobulins
4) By Blood Transfusions: Leukoreduced RBC Transfusions, Emergency Transfusions, Phenotypically Matched RBC Transfusions
5) By Splenectomy: Laparoscopic Splenectomy, Prophylactic Treatments Post-Splenectomy, Open Splenectomy
Which Trends Are Affecting The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Framework?
Major companies engaged in the warm autoimmune hemolytic anemia (WAIHA) treatment market are prioritizing the development of innovative therapies, such as monoclonal antibodies, to meet existing clinical needs and improve patient outcomes. Monoclonal antibodies are laboratory-engineered proteins designed to specifically target certain immune cells or pathways, thereby reducing the destruction of red blood cells in warm autoimmune hemolytic anemia. For instance, in July 2023, IASO Biotechnology, a biopharmaceutical company from China, announced that the U.S. Food and Drug Administration (FDA) had granted approval for IASO-782 Injection to proceed with clinical studies in the United States for autoimmune hematological conditions like warm autoimmune hemolytic anemia (WAIHA) and primary immune thrombocytopenia (ITP). This fully human monoclonal antibody targets CD19 and features Fc mutations aimed at increasing ADCC activity while maintaining other Fc functions. It works by selectively depleting CD19+ B cells, plasma blasts, and some plasma cells, which are responsible for producing auto-reactive antibodies. Due to its distinct mechanism, IASO-782 has the potential to treat autoimmune illnesses caused by pathogenic B and plasma cells, such as ITP and AIHA.
Which Industry Players Are Present In The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market?
Major companies operating in the warm autoimmune hemolytic anemia (waiha) treatment market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Agios Pharmaceuticals Inc., Incyte Corporation, Mallinckrodt Pharmaceuticals, Xencor Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Immunovant Inc., Zenas BioPharma Inc., Alexion Pharmaceuticals Inc., CSL Behring, Grifols S.A., Octapharma AG, Kedrion Biopharma, LFB Group, ADMA Biologics Inc., Pfizer Inc., Bristol-Myers Squibb Company, Amgen Inc.
Access The Complete Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Report:
Which Region Has The Strongest Presence In The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market?
North America was the largest region in the warm autoimmune hemolytic anemia (WAIHA) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the warm autoimmune hemolytic anemia (waiha) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=24426&type=smp
Browse Through More Reports Similar to the Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market 2026, By The Business Research Company
Autoimmune Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report
Anemia And Other Blood Disorder Drugs Market Report 2026
Hemostasis Products Market Report 2026
https://www.thebusinessresearchcompany.com/report/hemostasis-products-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model